79 results about "Heart Injury" patented technology

The present invention provides a method of post-conditioning reperfusion of an organ or tissue injured by ischemia. Also provided is a method of treating a myocardial infarction in a subject to prevent injury to the heart following reperfusion of the heart.

A system simulates stimulation of scar tissue identified as hyper-enhanced areas in a medical image with variable luminance thresholds and categorizes partially-viable myocardium as distinct from non-viable scar tissue. A cardiac function analysis system includes a repository of imaging data representing a 3D volume comprising a patient heart. A model processor provides a model of the patient heart using the imaging data said model being for use in allocating electrical properties to model parameters determining electrical conductivity associated with image data classified as, (a) scar tissue, (b) impaired tissue and (c) normal heart tissue. The electrical properties allocated to scar tissue are different to electrical properties allocated to normal tissue. A stimulation processor simulates electrical stimulation of the patient heart using the model to identify risk of heart impairment.

The invention provides a method for directionally differentiating a multipotential stem cell in vitro into a myocardial cell and provides a culture medium for establishing myocardial cell differentiation by means of induction in vitro under a three-dimensional suspension condition. The culture medium comprises a differential medium for induced differentiation of a multipotential stem cell into a precursor cell of mesoblast, a differential medium for differentiating the precursor cell of mesoblast into the myocardial cell and a long-term maintaining culture medium of the myocardial cell. The method provided by the invention is simple and reliable, low in cost, stable and efficient and high in safety. By adopting a suspension culture system, high-quality myocardial cells can be industrially produced without any subsequent screening and purifying steps, can be directly used for application demands of scientific research of heart development, cell therapy of heart diseases, transplanting due to cardiac trauma and drug screening, and has inestimable scientific, social and economical benefits.

The present invention provides compositions comprising mesenchymal stem cells (MSCs), and methods for their novel use in the repair of cardiac damage and treatment of inflammatory diseases. The invention also provides methods for using TSG-6 protein that is secreted by MSCs under certain conditions, for repair of cardiac damage and inflammatory disease. The compositions of the invention may be particularly useful in restoring cardiac function following cardiac damage, including, but not limited to, myocardial infarction, as well as in reducing symptoms of inflammatory disease.

The invention relates to methods for treating a patient suffering from acute coronary syndrome, but who is not suffering from a Q-wave myocardial infarction, comprising administration of a therapeutically effective amount of a GLP-1 molecule. The GLP-1 can be self-administered, and can be administered in one or more doses, as needed, on an intermittent or continuous basis, to optimize metabolism in cardiac tissue and to prevent cardiac damage associated with ischemia.

The invention provides a method of treating diastolic dysfunction, e.g., diastolic dysfunction with preserved ejection fraction, in a subject. The method comprises administering to the subject in an amount effective to treat the diastolic dysfunction a cardiac metabolic modifier, as described herein. In some embodiments, the diastolic dysfunction is characterized by (i) a lack of increased late INa in cardiomyocytes, (ii) an increase in myofilament calcium sensitivity, or (iii) a combination thereof. In some embodiments, the subject does not suffer from a cardiac injury or a structural heart disease, as described herein. Further provided are a method of treating heart failure with preserved ejection fraction in a subject, a method of treating acute decompensated heart failure, a method of modulating myofilament calcium sensitivity in a subject, and a method of treating a condition associated with or caused by increased myofilament calcium sensitivity.

The invention discloses a teabag capable of relieving alcoholic liver, brain and heart injuries and a preparation method. The teabag is produced and prepared by taking radix puerariae, fructus crataegi, hovenia dulcis thumb, flos chrysanthemi, rhizoma phragmitis and fructus chaenomelis lagenariae as raw materials according to a certain weight ratio through the processes of picking and selecting, smashing, adding of an appropriate amount of taurine, stevioside and citric acid, uniform mixing, packaging, sterilizing and the like. The teabag is suitable for treating the injuries including the digestive system ulcers, the serious liver injuries, the nervous system injuries and the circulatory system injuries which are brought by heavy drinking.

The invention provides a kit and a method for in vitro directional differentiation of human-derived iPS stem cells into myocardial cells. By virtue of a nutrient solution provided by the kit disclosed by the invention and in accordance with the method disclosed by the invention, the efficient and directional differentiation of the iPS stem cells into the myocardial cells is promoted. The kit and the method disclosed by the invention are simple and reliable, stable and efficient and high in safety, and the differentiation proportion of the multipotential stem cells into the myocardial cells is significantly increased to be greater than 90%. Meanwhile, the kit and a culture medium disclosed by the invention are applicable to the large-scale production of high-quality myocardial cells, without subsequent screening and purifying steps; and the kit and the culture medium are directly applicable to heart development scientific researches, cell therapy of heart diseases, transplantation for heart injury and application demand of drug screening.

The invention relates to one section of thymosin beta 4 derivatives with high bioactivity which can be used to repair cornea, skin, and heart injury.

The present invention is related to benzothiophen-2-carbonylguanidine derivatives, a preparation method thereof, and pharmaceutical compositions containing the same. The derivatives have potent inhibitory effect on the sodium / hydrogen exchanger NHE-I, improve the functional recovery of ischemia / reperfusion-induced heart injury in isolated ischemic heart models, and significantly reduce the myocardiac infarct size in in vivo ischemic animal models, thereby showing excellent cardioprotective effects. Also, the derivatives are protective of both neuronal cells and the brain as proven by their protective effects on neuronal cells from necrosis and apoptosis and by their ability to significantly reduce cerebral infarct sizes in in vivo ischemic brain models. The derivatives can be effectively used for the prevention and treatment of ischemic heart diseases such as myocardiac infarction, arrhythmia, angina pectoris and the like, and cerebrovascular diseases such as cerebral stroke and be used as cardioprotective agents to the patients undergoing reperfusion therapy including chemicals such as thrombolytic agents, or surgery such as coronary artery bypass and percutaneous transluminal coronary angioplasty.

The invention provides a Radix Glycyrrhizae extract capable of reducing toxicity of drugs to heart. The extract is derived from the root or the rhizome of licorice belonging to the Leguminosae such as Glycyrrhiza uralensis Fisch., Glycyrrhiza inflata Bat. and Glycyrrhiza glabra L.; and mainly contains triterpenoid saponins and flavone glycosides as active ingredients, wherein the content of triterpenoid saponins is 10-30%, and the content of flavone glycosides is 25-80%. The in vivo and in vitro tests show that the Radix Glycyrrhizae extract has distinct protective effect on heart injury induced by adriamycin while not weakening the antitumor effect of anthracycline antitumor drugs; and can be used for preventing and reducing the toxicity of anthracycline drugs to heart, so as to improve the therapeutic effect and clinic application range thereof. The Radix Glycyrrhizae extract can be used for preparing medicines for reducing the toxicity of anthracycline drugs to heart.

The invention discloses a disposable pericardium chest puncture needle which comprises a needle core, a drainage catheter and a drainage catheter joint chair. The needle core is arranged in the drainage catheter, a drainage cavity is arranged in the drainage catheter joint chair, the drainage cavity is internally provided with a rubber block, the needle core extends toward the drainage catheter joint chair and passes through the rubber block, one end of the needle core is provided with a needle core joint base which is hermetically matched with the drainage catheter joint chair, and the drainage catheter joint chair is provided with a side drainage tube which is provided with a three-way control device. According to the disposable pericardium chest puncture needle provided by the invention, during puncture and drainage, the puncture needle can retreat to prevent the tip from damaging heart and lug tissues. A gas one-way valve and an emergency end cover on the side drainage tube can be used as an emergent rescue tool for patients with severe tension pneumothorax. The three-way control device and the three-way side interface are arranged on the side drainage tube. The switch effect can be performed by the three-way control device as well as puncture and drainage of hydropericardium and pleural effusion and pericardium and chest injection of medication can be performed.

The invention relates to novel pharmacological action of traditional Chinese medicine salvianolic acid A and application thereof in the preparation of products for preventing, relieving and / or treating pulmonary arterial hypertension and its complications. The salvianolic acid A has the advantages that the salvianolic acid A has the pharmacological action of relieving pulmonary circulation pressure rise, the pharmacological actions of relieving right heart failure due to pulmonary arterial hypertension, improving right ventricular hypertrophy and right ventricular enlargement, improving heart injury due to pulmonary arterial hypertension, and restoring from heart failure, and the pharmacological actions of lowering endothelin-1 level in pulmonary tissues, relieving pulmonary arterial remodeling and improving pathologic damage of pulmonary tissues; the salvianolic acid A is a monomer compound extracted from Salvia miltiorrhiza, has low toxicity, has a wide source range of material, has promising application and development prospect, is an ideal novel traditional Chinese medicine monomer for treating pulmonary arterial hypertension and its complications, and may be applied to prepare products for preventing, relieving and treating pulmonary arterial hypertension and its complications, such as chronic obstructive pulmonary emphysema, chronic pulmonary heart disease and heart failure.

The invention relates to markers for acute myocardial infarction (AMI), particularly markers that may be used in the rapid and accurate diagnosis of AMI or reinfarction. A method of diagnosing cardiac injury comprising identifying an elevated concentration of cardiac myosin binding protein C (cMyBP-C) or a fragment thereof or myosin regulatory light chain 2 (MLC2) or a fragment thereof in a sample obtained from a subject.

The invention relates to an application of p-hydroxyphenylacetic acid in prevention and / or treatment of cardiovascular diseases. The invention finds for the first time that p-hydroxyphenylacetic acidhas a good treatment effect on vascular and cardiac injuries. For zebra fish interbody vascular (ISV) injury and subintestinal vein (SIV) growth conditions induced by a vascular endothelial cell growth factor receptor inhibitor (PTK787), p-hydroxyphenylacetic acid has a remarkable effect of promoting angiogenesis, and the generation number and the length of blood vessels can be obviously increased. The traditional Chinese medicine composition has a remarkable heart protection effect on heart failure of zebra fish induced by verapamil, arrhythmia induced by terfenadine and p-hydroxyphenylaceticacid, and can obviously reduce cardiac dilatation, relieve venous congestion and promote the heart rate to tend to be normal.

The present invention relates to the use of an EMMPRIN inhibitor for preventing and / or treating cardiac damage arising after an ischemic process followed by reperfusion. The authors of the present invention have observed that EMMPRIN expression increases in subjects who have suffered ischemia / reperfusion, ascertaining that an EMMPRIN inhibitor is capable of reducing the cardiac damage caused after ischemia followed by reperfusion, both in vitro and in vivo.

The invention belongs to the technical field of medical instruments, and particularly relates to a heart stent for a magnetomotive heart auxiliary power system and a system. The heart stent for the magnetomotive heart auxiliary power system comprises a movable block stent, the movable block stent is used for supporting a magnetic movable block of the magnetomotive heart auxiliary power system, and a stabilizing piece is arranged on the movable block stent; the stabilizing piece is used for fixing the loose piece support so that the relative position of the loose piece support and the heart can be fixed, and the magnetic loose piece is movably connected with the loose piece support so that the magnetic loose piece can move in the direction facing and deviating from the heart. According to the scheme, the magnetic movable blocks are arranged on the heart in a support mode, the connection difficulty of the magnetic movable blocks and the heart can be greatly reduced, heart damage caused by connection of the magnetic movable blocks can be greatly reduced, arrangement of more magnetic movable blocks becomes reality, different positions of the heart can be better assisted in a differentiated power mode, and the control precision of the heart auxiliary power is greatly improved.

The invention provides a use of sulfoxide compounds in preparing drugs for preventing humans, with thoracic and abdominal tumors, to be subjected to radiotherapy from being attacked by radioactive cardiac injury, radioactive pancreatic injury and radioactive gastritis. The sulfoxide compounds have the excellent effect in preventing the humans with the thoracic and abdominal tumors from being attacked by the radioactive cardiac injury, the radioactive pancreatic injury and the radioactive gastritis.

The invention relates to application of bioactive polypeptide PACAP in preparing drugs for preventing, treating or restoring cardiac trauma diseases. The bioactive polypeptide PACAP drugs can significantly prevent and relieve toxicity of radioactive cardiac traumas, the pathological change and heart function change of the radioactive cardiac traumas are repaired, and a novel sole targeted therapystrategy is provided for malignant chest tumor and radiotherapy patients with radioactive myocardial tissue traumas as features.

The present invention provides an isolated population of cortical bone stem cell (CBSC)-derived exosomes, and compositions comprising the exosomes and / or RNA thereof which are used for promoting cardiac repair when being delivered to a diseased heart.

The invention discloses an exposure device and a method for minimally invasive operating room septal defects, and relates to the technical field of medical apparatus and instruments. The invention solves the cardiac injury caused easily in the process of stretching and exposing the ventricular septal defect, The technical scheme comprises a hand-held box, a tube fixedly connected with the hand-held box and a first air bag fixedly connected with the outer wall of the tube, wherein the first air bag is circumferentially arranged along the tube body; The hand-held box is provided with a syringe for storing normal saline, and the pipe is provided with a liquid infusion pipe which is respectively communicated with the syringe and the first air bag at two ends. The injection barrel is movably connected with a sealed piston, and the hand box is movably connected with an operation rod for driving the sealed piston to move, which has the effects of reducing heart injury and simplifying the operation of pulling and exposing the ventricular septal defect.

The invention provides a composition for activating cardiac regeneration. The composition contains an Erk1 / 2 phosphorylation level positive regulator. The invention further relates to application of Mek1 / 2 protein, Erk1 / 2 dephosphorylated inhibitor, hydrogen peroxide or NOX family proteins in preparing a cardiac regeneration activating medicine. Upon experiments, the invention discovers a signal pathway which is capable of activating cardiac regeneration capacity, and by regulating the signal pathway from various links, the cardiac regeneration capacity is activated. By operating a heart injury surface and activating the cardiac regeneration capacity, the composition can be used for effectively treating heart injury and reducing death rate.

Compositions and methods for improving cardiac structure and / or function in subjects in need thereof. The methods include administering to a subject a succinate dehydrogenase inhibitor in an amount and for a time effective to elicit an improvement in cardiac structure and / or function. The subjects include subjects suffering from cardiac damage, such as damage resulting from myocardial infarction or other cardiac events. Improvements in cardiac function include one or more of an increase in cardiomyocyte proliferation, an increase in ejection fraction, an increase in fractional shortening, a decrease in left ventricle internal diameter diastole, and a decrease in left ventricle internal diameter systole. Improvements in cardiac structure include one or more of decreased fibrosis, an increase in myocardial thickness, an increase in coronary artery formation, an increase in capillary density, an increase in revascularization, and a decrease in myocardial lesion size. Compositions for performing the methods are provided.

The invention provides a pharmacological mechanism of radix astragali seu hedysari pulse-activating decoction capable of preventing radiation-induced heart injury. A preparation method comprises the following steps: adding water into radix astragali seu hedysari for decocting, and then filtering; concentrating filtrate till every 1ml filtrate is equivalent to 1 to 2g of raw medicinal material; precipitating with ethanol by two times, wherein the solution contains 75 percent of ethanol in the first time, the solution contains 85 percent of ethanol in the second time; recovering the ethanol and concentrating till every 1ml of ethanol is equivalent to 10g of the raw medicinal material; adding chrysanthemum indicum flower, fructus crataegi, semen raphanin, radix glycyrrhizae and wolfberry fruit and smashing; adding water for soaking, extracting, concentrating and recovering ethanol; adding honey, isomaltose and wine-related yeast species for performing initial fermentation; finally filtering, precipitating, sterilizing and tanking. The radix astragali seu hedysari pulse-activating decoction has the beneficial effects of effectively improving the cardiac function of an irradiated rat, lowering the serum levels of the troponin and creatine kinase-myocardial band (CK-MB) serving as heart injury symbolic molecules, adjusting signal molecules relevant to fibrosis injury such as extracellular matrix, reconstructed enzyme, inflammatory cytokines / chemotactic factor and TGF-beta, and effectively protecting irradiated heart.

The invention discloses an application of an alkaloid compound in preparation of a product for preventing and / or treating heart injury, activity research is performed on the alkaloid compound, and it is verified that the alkaloid compound can inhibit apoptosis induced by myocardial toxicity. According to the present invention, by down-regulating the expression level of p-JNK and / or Cleaved-Caspase-3, the myocardial apoptosis induced by the anthracycline drug DOX is inhibited so as to alleviate the myocardial cytotoxicity effect, achieve the myocardial cytotoxicity prevention and / or treatment effect, and can be used for preparing drugs for preventing and / or treating myocardial injury related diseases.

The invention discloses an application of Ctrp15 in preparation of a product for promoting angiogenesis and improving ischemia-related cardiac functions. The invention provides an application of Ctrp15 protein or a coding gene thereof or a substance taking the Ctrp15 protein as an active component in at least one of the following applications. 1) preparing a product for treating heart injury; 2) preparing a product for relieving heart injury; and 3) preparing a product for improving the cardiac function repair capability after heart injury. The invention finds that the Ctrp15 protein secreted by the skeletal muscle induced by movement can improve the collateral angiogenesis after myocardial infarction and finally promote the repair of cardiac functions by researching whether the Ctrp15 regulates the collateral angiogenesis or not in the movement process and researching a molecular mechanism.